<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00518154</url>
  </required_header>
  <id_info>
    <org_study_id>Ref. 1663</org_study_id>
    <nct_id>NCT00518154</nct_id>
  </id_info>
  <brief_title>Pilot Study of Pyridostigmine Upon Immune Activation in HIV-1 Patients Who Have an Inadequate Immune Response</brief_title>
  <official_title>Pilot Study of an ACh-E Inhibitor Upon Immune Activation Markers in HIV-1 Infected Patients Receiving Highly Active Antiretroviral Therapy (HAART) Showing an Incomplete Immune Response.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the addition of Pyridostigmine to Highly
      Active Antiretroviral Therapy (HAART) increases the number of CD4+ T-cells in discordant
      patients in which viral load diminishes, but T-cell levels remain low after the initiation of
      treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In HIV-1 infected patients, HAART suppresses viral replication, reflected by a reduced viral
      load, and a recovery in the frequency of CD4+ T-cells. The latter is associated with a
      reduced risk for developing opportunistic infectious diseases, and death. T-cell recovery,
      however, is highly variable within individuals, suggesting that virological eradication is
      but one factor of it.

      A phenomenon known as Immune Discordance has been well known. It reflects a subpopulation -as
      high as 30% of patients- in whom there is an adequate suppression of viral replication, but
      CD4+ cell levels rise modestly (below safety levels). In this setting, patients remain
      susceptible to develop opportunistic infections, have disease progression, and die. Various
      mechanisms have been proposed, but one common factor is enhanced CD4+-cell activation,
      leading to cell dysfunction and apoptosis.

      It is known that an inflammatory response is able to activate the anti-inflammatory
      cholinergic pathway, in which acetylcholine (ACh) is released and in turn activates nicotinic
      receptors in macrophages. The result is a diminished synthesis of inflammatory cytokines such
      as TNF-α, and IL-1. We have recently shown in an ex-vivo, proof-of-concept study carried in
      HIV-infected subjects in early phases of the infection (not requiring specific treatment)
      that Pyridostigmine diminishes CD4+-cell activation and an increase in the subpopulation of
      regulatory T-cells (T-reg).

      Pyridostigmine, an ACh-esterase inhibitor, has been shown to be safe in other populations,
      including healthy Gulf War military personnel, and patients with Myasthenia Gravis. Its
      hypothetical effect is by reducing the degrading rate of the naturally occurring ACh
      (released by the vagus nerve) by the enzyme ACh-esterase. This in turn enhances its coupling
      to nicotinic receptors in macrophages that, according to our previous study (unpublished
      data), improves the T-cell milieu, diminishes T-cell activation (a well known trigger for
      apoptosis), and enhances T-reg proliferation.

      The purpose of this study is to determine whether the addition of Pyridostigmine to Highly
      Active Antiretroviral Therapy (HAART) increases the number of CD4+ T-cells in discordant
      patients in which viral load diminishes, but T-cell levels remain low after the initiation of
      treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CD4+ Cell Count Change Between Basal and Week 16 of Additive Treatment</measure>
    <time_frame>16 weeks after initiation of pyridostigmine</time_frame>
    <description>Change in total CD4+ T-cell number from baseline to addition of pyridostigmine</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be taking oral Pyridostigmine 30mg tid, as well as their usual antiretroviral treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyridostigmine tablets</intervention_name>
    <description>Patients will take 30mg tid PO for 12 weeks</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Mestinon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 infected subjects 18 years of age or older

          -  Receiving HAART for at least two years

          -  At least a viral load determination per year since HAART initiation, all undetectable

          -  Patient's status is Immunological Non Responder (InR), that is, his or her viral load
             is reduced, but CD4+ cell count has not raised accordingly

          -  Current viral load: undetectable

          -  Patient agrees and signs informed consent

        Exclusion Criteria:

          -  Concomitant active infectious or neoplastic disease

          -  History of new AIDS-defining events during HAART

          -  Pregnancy or breast-feeding

          -  Patients who have been subjects of an investigational agent, chemotherapy or
             radiotherapy within the previous 28 days

          -  Subjects requiring treatment for Tuberculosis

          -  Subjects unable to follow, or comply with the protocol interventions

          -  Subjects receiving immunosuppressive treatment, including corticosteroids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan Sierra-Madero, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Dept. of Infectious Diseases, INNSZ</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jorge Alcocer-Varela, MD</last_name>
    <role>Study Director</role>
    <affiliation>Dept. of Immunology, INNSZ</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sergio I Valdés-Ferrer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Neurology, INNSZ</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán</name>
      <address>
        <city>Tlalpan</city>
        <state>Ciudad De México</state>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sergio I. Valdés-Ferrer</name>
      <address>
        <city>Mexico City</city>
        <state>DF</state>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>http://www.innsz.mx</url>
    <description>Institute's web page</description>
  </link>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>August 17, 2007</study_first_submitted>
  <study_first_submitted_qc>August 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2007</study_first_posted>
  <results_first_submitted>October 10, 2017</results_first_submitted>
  <results_first_submitted_qc>October 24, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 14, 2019</results_first_posted>
  <last_update_submitted>October 24, 2019</last_update_submitted>
  <last_update_submitted_qc>October 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</investigator_affiliation>
    <investigator_full_name>Sergio I. Valdés-Ferrer, MD, PhD</investigator_full_name>
    <investigator_title>Investigator, Depatment of Infectious Diseases</investigator_title>
  </responsible_party>
  <keyword>AIDS</keyword>
  <keyword>Immunological non-responders</keyword>
  <keyword>Neuroimmune modulation</keyword>
  <keyword>Pyridostigmine</keyword>
  <keyword>Treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pyridostigmine Bromide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pyridostigmine</title>
          <description>Patients will be taking oral Pyridostigmine 30mg tid, as well as their usual antiretroviral treatment. The study is open-label, proof-of-concept.
Pyridostigmine tablets: Patients will take 30mg tid PO for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Change in Circulating CD4+ T-cell Count (Baseline vs. 16 Weeks</title>
          <description>Participants will receive pyridostigmine 30mg three times per day for a period of 16 weeks. Pyridostigmine will be in addition (add-on) to their usual antiretroviral treatment schedule.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>CD4+ Cell Count Change Between Basal and Week 16 of Additive Treatment</title>
        <description>Change in total CD4+ T-cell number from baseline to addition of pyridostigmine</description>
        <time_frame>16 weeks after initiation of pyridostigmine</time_frame>
        <population>Change in total CD4+ T-cell counts</population>
        <group_list>
          <group group_id="O1">
            <title>Pyridostigmine</title>
            <description>Patients will be taking oral Pyridostigmine 30mg tid, as well as their usual antiretroviral treatment. The study is open-label, proof-of-concept.
Pyridostigmine tablets: Patients will take 30mg tid PO for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>CD4+ Cell Count Change Between Basal and Week 16 of Additive Treatment</title>
          <description>Change in total CD4+ T-cell number from baseline to addition of pyridostigmine</description>
          <population>Change in total CD4+ T-cell counts</population>
          <units>CD4+ T-cell count/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153.2" spread="43.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>16 weeks</time_frame>
      <desc>We will use the standard definition of adverse event: &quot;Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant’s participation in the research, whether or not considered related to the participant’s participation in the research.&quot;</desc>
      <group_list>
        <group group_id="E1">
          <title>Pyridostigmine</title>
          <description>Patients will be taking oral Pyridostigmine 30mg tid, as well as their usual antiretroviral treatment
Pyridostigmine tablets: Patients will take 30mg tid PO for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Carlos Aguilar Salinas, Director of Ethics in Human Research Committee</name_or_title>
      <organization>Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán</organization>
      <phone>5554870900 ext 4524</phone>
      <email>carlos.aguilars@incmnsz.mx</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

